0QF:FRA
Moderna
167,36 €
arrow_downward
-0,92%(-1,56) 1 д.
2.10, 22:00:00 ч. Гринуич+2 · EUR
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за 0QF…
Отваряне
169,66 €
Висока
171,20 €
Ниска
163,30 €
Пазарна кап.
75,86 млрд.
Ср. обем
2,99 хил.
Обем
919,00
Най-висока цена за 52 седм.
183,40 €
Най-ниска цена за 52 седм.
19,26 €
Брой служители
5 хил.
Отваряне
169,66 €
Висока
171,20 €
Ниска
163,30 €
Пазарна кап.
75,86 млрд.
Ср. обем
2,99 хил.
Обем
919,00
Най-висока цена за 52 седм.
183,40 €
Най-ниска цена за 52 седм.
19,26 €
Брой служители
5 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
Stocktwits
·
преди 12 часа
SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Simply Wall Street
·
преди 1 ден
Moderna (MRNA) Stock Looks Too Expensive For Its Sales Story
Invezz
·
преди 2 дни
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
Investing.com
·
преди 2 дни
Moderna to join Nasdaq-100 index on Oct. 9, replacing Warner Bros.
Профил
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Всичко за Moderna
Главен изпълнителен директорСтефан Бансел
Служители4,7 хил.
Дата на основаванесеп 2010
Централен офис-
Бранш-
Уебсайтmodernatx.com